Search research articles
Contact Us
Filters
Showing results (161-170 of 253) with videos related to
Page
of 26
Sort By:
Leukemia Research
|
September 9, 2006
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project
June M McKoy, Cara Angelotta, Charles L Bennett, et al.
British Journal of Haematology
|
May 29, 2010
All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma
Amareshwar T K Singh, Andrew M Evens, Reilly J Anderson, et al.
British Journal of Haematology
|
April 27, 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M Evens, Jeffrey Cilley, Taylor Ortiz, et al.
European Journal of Cancer Care
|
February 15, 2022
Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey
Angela J Fong, Andrew M Evens, Elisa V Bandera, et al.
JACC. Cardiooncology
|
May 22, 2024
Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma
Jenica N Upshaw, Jason Nelson, Benjamin Sweigart, et al.
Leukemia & Lymphoma
|
August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
William B Pearse, Adam M Petrich, Leo I Gordon, et al.
British Journal of Haematology
|
April 19, 2017
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL
Natalie Galanina, Sonali M Smith, Chuanhong Liao, et al.
Blood
|
February 7, 2019
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Eric D Hsi, Hongli Li, Andrew B Nixon, et al.
Cancer Causes & Control : CCC
|
April 25, 2025
Sociodemographic, medical, health behavior, and psychosocial factors associated with COVID-19 diagnoses in the New Jersey cancer survivor cohort
Sharon Manne, Adana A M Llanos, Hari S Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2015
Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting
Michael Lishner, Irit Avivi, Jane F Apperley, et al.
Page
of 26
Search research articles
Search
Showing results (161-170 of 253) with videos related to
Sort By:
Page
of 26
Leukemia Research
|
September 9, 2006
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project
June M McKoy, Cara Angelotta, Charles L Bennett, et al.
British Journal of Haematology
|
May 29, 2010
All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma
Amareshwar T K Singh, Andrew M Evens, Reilly J Anderson, et al.
British Journal of Haematology
|
April 27, 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M Evens, Jeffrey Cilley, Taylor Ortiz, et al.
European Journal of Cancer Care
|
February 15, 2022
Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey
Angela J Fong, Andrew M Evens, Elisa V Bandera, et al.
JACC. Cardiooncology
|
May 22, 2024
Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma
Jenica N Upshaw, Jason Nelson, Benjamin Sweigart, et al.
Leukemia & Lymphoma
|
August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
William B Pearse, Adam M Petrich, Leo I Gordon, et al.
British Journal of Haematology
|
April 19, 2017
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL
Natalie Galanina, Sonali M Smith, Chuanhong Liao, et al.
Blood
|
February 7, 2019
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Eric D Hsi, Hongli Li, Andrew B Nixon, et al.
Cancer Causes & Control : CCC
|
April 25, 2025
Sociodemographic, medical, health behavior, and psychosocial factors associated with COVID-19 diagnoses in the New Jersey cancer survivor cohort
Sharon Manne, Adana A M Llanos, Hari S Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2015
Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting
Michael Lishner, Irit Avivi, Jane F Apperley, et al.
Page
of 26